BLAIV (INFUSION)INJECTABLEPriority Review
Approved
Mar 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
69
Data completeness
5/8 — Partial
Priority Review
SOLIRIS (eculizumab) by AstraZeneca is complement inhibitors [moa]. Approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, myasthenia gravis. First approved in 2007.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOLIRIS (eculizumab) is a monoclonal antibody complement inhibitor approved in 2007 for treating generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) in adult patients. It works by blocking C5 complement activation, preventing the formation of the membrane attack complex that causes tissue damage in these autoimmune neurological conditions. SOLIRIS represents a foundational therapy in complement-targeted immunosuppression and established the complement inhibitor class as a treatment paradigm for rare neurological disorders.
$0.2BPart D
Mechanism of Action
Complement Inhibitors
Pharmacologic Class:
Complement Inhibitor
Worked on SOLIRIS at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.